Chicago, IL, December 26, 2017
ADVAITE, a clinical-stage biopharmaceutical company that is developing innovative therapeutic, diagnostic and healthcare solutions to treat ocular surface disorders, today announced its Co-Founder, and Chief Scientific Officer Sandeep Jain, MD, was named ‘Inventor of the Year’ by University of Illinois at Chicago.
The Inventor of the Year Award honors an outstanding inventor or team of inventors at University of Illinois at Chicago who have made a contribution to the development of intellectual property that significantly impacts their field and society. The award is given based on the criteria of creativity, novelty, invention’s potential for further development and commercialization/adoption and the commercial benefit to society. An internal University committee made up of tech managers and members from diverse disciplines, many of whom are distinguished university professors, serves in selecting the UIC Inventor of the Year.
Dr. Jain is a National Eye Institute/NIH funded clinician-scientist and an Associate Professor in Ophthalmology at the University of Illinois at Chicago Department of Ophthalmology. He is the Director of the UIC Dry Eye & ocular GVHD clinic.
“Congratulations, Sandeep, on this very well deserved recognition! You have distinguished yourself and your team and advanced basic and translational science to cure dry eye and ocular surface disease! Best wishes for continued success” said Dimitri Azar, MD, MBA, Senior Director, Verily Life Sciences; Executive Dean and Distinguished Professor, University of Illinois College of Medicine. “Exemplary work! Very much deserved. Thank you for your dedication to science, innovation and patient care” said Mark Rosenblatt, MD, PhD, MBA, Professor and Head, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago.
“I am honored to have been selected for this prestigious award” said Dr. Jain. “Patients with severe ocular surface diseases suffer from debilitating symptoms of ocular discomfort that reduces their quality of life. Our goal at ADVAITE is to rapidly develop therapies that can alleviate suffering of these patients” He added.
ADVAITE is a clinical-stage biopharmaceutical company that is developing innovative therapeutic, diagnostic and healthcare solutions to treat ocular surface disorders. ADVAITE has established a partnership with University of Illinois at Chicago, a public research university. The lead product, ADV100, is a repurposed drug that is being developed for the treatment of cicatrizing ocular surface diseases like Steven Johnson Syndrome, Ocular Mucous Membrane Pemphigoid and Ocular GVHD. ADV200 is a panel of four tear fluid biomarkers (BM1-4) that serve as indicators of processes that contribute to pathophysiology of ocular surface diseases and will be used to initiate a therapy (e.g. ADV100) and follow response to the therapeutic intervention.Investor Relations Contact